Health And Wellness Trademark Review 9 June, 2020
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
You may also be interested in...
Manufacturers developing devices to remove tissue in the prostate should provide the US FDA with follow-up information on patients that include certain indirect data about the long-term safety outcomes of using their product, according to a final agency guidance.
Draft guidance from the US FDA updates the agency’s recommendations around research to support new devices for the treatment of prostate enlargement.
No device-related warning letters were released by the US FDA the week of 14 July.